End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.06 CNY | -2.03% | +3.49% | -20.02% |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.02% | 763M | - | ||
+51.54% | 795B | C+ | ||
-7.20% | 350B | C+ | ||
+18.67% | 328B | B- | ||
+7.48% | 294B | C+ | ||
+17.89% | 245B | B+ | ||
+1.60% | 222B | A+ | ||
+11.32% | 215B | B- | ||
+3.64% | 160B | C+ | ||
-3.96% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301263 Stock
- Ratings Guangdong Taienkang Pharmaceutical Co., Ltd.